Castration refractory prostate cancer: cinderella finally comes to the ball.
Simon
S
Chowdhury
Peter
P
Harper
Thomas
T
Powles
D000736:Androstenes; D000737:Androstenols / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood; D014020:Tissue Extracts / Q000009:adverse effects / Q000627:therapeutic use
D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D015507:Drugs, Investigational; D043823:Taxoids; D014020:Tissue Extracts; D013739:Testosterone; C552428:cabazitaxel; C511774:sipuleucel-T; C089740:abiraterone